| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2017NatCo...8.1130C |
| P356 | DOI | 10.1038/S41467-017-01236-6 |
| P932 | PMC publication ID | 5654983 |
| P698 | PubMed publication ID | 29066712 |
| P50 | author | Georg Schett | Q73565915 |
| P2093 | author name string | Oliver Distler | |
| Chih-Wei Chen | |||
| Raymund E Horch | |||
| Jörg H W Distler | |||
| Kolja Gelse | |||
| Barbora Šumová | |||
| Ladislav Šenolt | |||
| Alfiya Distler | |||
| Andreas Ramming | |||
| Ingo Ludolph | |||
| Christina Bergmann | |||
| Tatjana Mallano | |||
| Debomita Chakraborty | |||
| P2860 | cites work | Role of the TAK1-NLK-STAT3 pathway in TGF-beta-mediated mesoderm induction | Q24314568 |
| Cellular and molecular mechanisms of fibrosis | Q24648892 | ||
| Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality | Q24685515 | ||
| STAT3 inhibitors for cancer therapy: Have all roads been explored? | Q27021266 | ||
| Smad-dependent and Smad-independent pathways in TGF-beta family signalling | Q28208250 | ||
| TGFβ signalling in context | Q28275410 | ||
| Smad transcription factors | Q28284775 | ||
| JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure | Q28392308 | ||
| Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 | Q28637521 | ||
| STATs in cancer inflammation and immunity: a leading role for STAT3 | Q29547203 | ||
| Non-Smad pathways in TGF-beta signaling | Q29620040 | ||
| TGF-beta signaling and the fibrotic response | Q29620099 | ||
| Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression | Q30754497 | ||
| Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity | Q33282964 | ||
| Molecular subsets in the gene expression signatures of scleroderma skin | Q33354088 | ||
| Functional roles of STAT family proteins: lessons from knockout mice | Q33643949 | ||
| A novel role of the STAT3 pathway in brain inflammation-induced human neural progenitor cell differentiation | Q34149483 | ||
| Transforming growth factor-beta and fibrosis | Q34232534 | ||
| The cytokine TGF-β co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells | Q34280534 | ||
| The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. | Q34310749 | ||
| Criteria for the classification of early systemic sclerosis. | Q34317138 | ||
| CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. | Q35006074 | ||
| Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease | Q35205442 | ||
| Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy | Q35597574 | ||
| Systemic sclerosis: a prototypic multisystem fibrotic disorder | Q35649427 | ||
| Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis | Q35710188 | ||
| Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis | Q35863725 | ||
| Strategies and Approaches of Targeting STAT3 for Cancer Treatment. | Q35884979 | ||
| Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age | Q36689956 | ||
| Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis | Q36777632 | ||
| Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation | Q37234131 | ||
| Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis | Q37306427 | ||
| Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis | Q37591872 | ||
| Biomarkers in systemic sclerosis | Q37730018 | ||
| Animal models of systemic sclerosis: prospects and limitations | Q37771308 | ||
| Biomarkers for skin involvement and fibrotic activity in scleroderma | Q37912251 | ||
| The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review | Q38126187 | ||
| Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model | Q38333221 | ||
| Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells | Q38353138 | ||
| The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis | Q38525172 | ||
| Biomarkers in systemic sclerosis: Their potential to predict clinical courses | Q38701985 | ||
| Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway. | Q38983015 | ||
| NF-κB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH. | Q39433792 | ||
| A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy | Q39697103 | ||
| Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines | Q39797434 | ||
| Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth | Q40020168 | ||
| SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo | Q40497236 | ||
| Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis | Q41592573 | ||
| STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates mouse ESC fates | Q41816518 | ||
| Systemic Sclerosis is a Complex Disease Associated Mainly with Immune Regulatory and Inflammatory Genes | Q41826432 | ||
| STAT3 selectively interacts with Smad3 to antagonize TGF-β | Q42147799 | ||
| A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. | Q42159140 | ||
| Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma | Q42506187 | ||
| Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells | Q43649346 | ||
| Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis | Q45084471 | ||
| Correction: Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin. | Q46435275 | ||
| Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis | Q46713770 | ||
| Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings | Q48014819 | ||
| JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. | Q50668149 | ||
| Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. | Q53302969 | ||
| 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. | Q54164380 | ||
| Scleroderma | Q54165664 | ||
| Stat3 signaling activation crosslinking of TGF-β1 in hepatic stellate cell exacerbates liver injury and fibrosis. | Q54332913 | ||
| JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. | Q54513818 | ||
| Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. | Q54535414 | ||
| Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1 | Q71893601 | ||
| Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway | Q79405603 | ||
| Targeting STAT3 in cancer: how successful are we? | Q82824786 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1130 | |
| P577 | publication date | 2017-10-24 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis | |
| P478 | volume | 8 |
| Q89976304 | Administration of Steamed and Freeze-Dried Mature Silkworm Larval Powder Prevents Hepatic Fibrosis and Hepatocellular Carcinogenesis by Blocking TGF-β/STAT3 Signaling Cascades in Rats |
| Q100512481 | An aberrant STAT pathway is central to COVID-19 |
| Q64117115 | Antitumor activity of Raddeanin A is mediated by Jun amino-terminal kinase activation and signal transducer and activator of transcription 3 inhibition in human osteosarcoma |
| Q92158428 | Cigarette Smoke Induced Lung Barrier Dysfunction, EMT, and Tissue Remodeling: A Possible Link between COPD and Lung Cancer |
| Q58799997 | Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment |
| Q89697410 | Discovery of 9O-Substituted Palmatine Derivatives as a New Class of anti-COL1A1 Agents via Repressing TGF-β1/Smads and JAK1/STAT3 Pathways |
| Q92072381 | Emerging Topical and Systemic JAK Inhibitors in Dermatology |
| Q92400156 | Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis |
| Q92554910 | Human adipose-derived stem cells support lymphangiogenesis in vitro by secretion of lymphangiogenic factors |
| Q95840967 | ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure |
| Q58785737 | Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1 |
| Q92624004 | Intermittent hypoxia mediated by TSP1 dependent on STAT3 induces cardiac fibroblast activation and cardiac fibrosis |
| Q90311616 | Mesoporous Silica Nanoparticles Trigger Liver and Kidney Injury and Fibrosis Via Altering TLR4/NF-κB, JAK2/STAT3 and Nrf2/HO-1 Signaling in Rats |
| Q55490826 | Novel classification for global gene signature model for predicting severity of systemic sclerosis. |
| Q91284099 | PU.1 controls fibroblast polarization and tissue fibrosis |
| Q89985624 | Pharmacological inhibition of STAT3 pathway ameliorates acute liver injury in vivo via inactivation of inflammatory macrophages and hepatic stellate cells |
| Q90736094 | Phenformin Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice without Affecting Immune Cell Infiltration |
| Q90061456 | Pro-fibrotic Activation of Human Macrophages in Systemic Sclerosis |
| Q52573450 | RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation. |
| Q89346556 | Systemic sclerosis: STAT3 - A key integrator of profibrotic signalling |
| Q90540850 | Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution |
| Q48522005 | Targeting Senescent Cells in Fibrosis: Pathology, Paradox, and Practical Considerations |
| Q58783029 | The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis |
| Q64940918 | Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. |
| Q99634063 | Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q92043634 | Tyrphostin AG490 reduces inflammation and fibrosis in neonatal obstructive nephropathy |
| Q58606339 | Ubiquitination in Scleroderma Fibrosis and Its Treatment |
| Q59329331 | Unraveling SSc Pathophysiology; The Myofibroblast |
| Q55294849 | pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. |
| Q90255266 | βIV-Spectrin/STAT3 complex regulates fibroblast phenotype, fibrosis, and cardiac function |
Search more.